Anal Carcinoma

News alerts, weekly reports and conference planners

No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2	capecitabine + mitomycin Sensitive: A2 - Guideline capecitabine + mitomycin Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + carboplatin Sensitive: A2 - Guideline cisplatin + carboplatin Sensitive : A2	cisplatin + carboplatin Sensitive: A2 - Guideline cisplatin + carboplatin Sensitive : A2
No biomarker	Anal Carcinoma	No biomarker	Anal Carcinoma	cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline cisplatin + 5-fluorouracil + capecitabine Sensitive : A2	cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline cisplatin + 5-fluorouracil + capecitabine Sensitive : A2
PD-L1 expression	Anal Carcinoma	PD-L1 expression	Anal Carcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
MSI-H/dMMR	Anal Carcinoma	MSI-H/dMMR	Anal Carcinoma	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1
PD-L1 overexpression + TMB-H	Anal Carcinoma	PD-L1 overexpression + TMB-H	Anal Carcinoma	EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials EGFR inhibitor + Immunotherapy Sensitive : C3	EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials EGFR inhibitor + Immunotherapy Sensitive : C3
CD163 expression	Anal Carcinoma	CD163 expression	Anal Carcinoma	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
CD4 expression	Anal Carcinoma	CD4 expression	Anal Carcinoma	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
PD-L1 expression	Anal Carcinoma	PD-L1 expression	Anal Carcinoma	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
PD-L1 amplification + PD-L2 amplification + TMB-H	Anal Carcinoma	PD-L1 amplification + PD-L2 amplification + TMB-H	Anal Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

Anal Carcinoma

Associations(22)

Associations
(22)